AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11051370
Drug: 3 mU
RxNorm normalized name: Orasep Reformulated Dec 2013 Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mU interferon TIW + ribavirin (1000‐1200 mg daily) for 6 months, increased to 5 mU TIW if HCV‐RNA positive at month 3
Trial: 11051370
Drug: 5 mU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mU interferon TIW + ribavirin (1000‐1200 mg daily) for 6 months
Trial: 24686046
Drug: Triple Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Injection (TI)
Trial: 24686046
Drug: Single Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Injection (SI)
Trial: 19890249
Drug: OATP1B3 polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OATP1B3 polymorphism 334T>G/699G>A in patients receiving MMF with tacrolimus or sirolimus
Trial: 17373169
Drug: Poly-L-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-L-lactic acid (PLLA)
Trial: 11896506
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg plus HCTZ 12.5 mg OD
Trial: 11896506
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg OD
Trial: 10459115
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil (5-FU) applied twice per day for 3 weeks
Trial: 10459115
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using topical 5-aminolevulinic acid (5-ALA) and irradiation with a 1200 W metal halogen lamp
Trial: 8590511
Drug: Edrophonium 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.125 mg.kg-1
Trial: 8590511
Drug: Edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.25 mg.kg-1
Trial: 8590511
Drug: Edrophonium 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.50 mg.kg-1
Trial: 2270599
Drug: Functional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional therapy with a free way space of greater than or equal to 1.0 mm and cuspid protected guidance
Trial: 2270599
Drug: Functional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional therapy
Trial: 22075171
Drug: Control hepatitis
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control hepatitis A vaccine
Trial: 31324360
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy with candesartan
Trial: 31324360
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy without candesartan
Trial: 23524061
Drug: Exploration phase
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploration phase (without trauma-focused treatment)
Trial: 19263337
Drug: 5 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/d of nonionic iron polymaltose complex + 25 IU vitamin E (as dl‐alpha‐tocopherol acetate) from 2 weeks of age
Trial: 17718920
Drug: Gel-pads
RxNorm normalized name: Medicated Pad
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-pads
Trial: 11509799
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of diabetes mellitus, older age, increased number of prescribed antihypertensive medications, lower hematocrit, absence of arrhythmias
Trial: 11509799
Drug: Younger age,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger age, increased number of prescribed antihypertensive medications, absence of arrhythmias
Trial: 3257913
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of leucovorin calcium (25 mg)
Trial: 3257913
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of leucovorin calcium (25 mg)
Trial: 3257913
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of leucovorin calcium (25 mg)
Trial: 3257913
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intramuscular administration
Trial: 3257913
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments (Intravenous, Intramuscular, Oral)
Trial: 23564914
Drug: Intraduodenal glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal glutamine (7.5 or 15 g)
Trial: 19741062
Drug: rt‐PA 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA 50 mg/2 h
Trial: 19741062
Drug: rt‐PA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt‐PA 100 mg/2 h
Trial: 15897822
Drug: Combined manipulative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined manipulative treatment, stabilizing exercises, and physician consultation
Trial: 8522469
Drug: Fluconazole administered
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole administered via feeding tube with concomitant enteral feeds
Trial: 8522469
Drug: Fluconazole administered
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole administered as intravenous infusion over 1 h
Trial: 2008781
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (received feedback on prescription errors)
Trial: 26902950
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 1-month formulation (PP1M)
Trial: 21048170
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g tranexamic acid in 100 mL normal saline solution
Trial: 21048170
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g tranexamic acid in 100 mL normal saline solution
Trial: 17403630
Drug: Preoperative RT-CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative RT-CT (radiotherapy 45 Gy on posterior pelvis + 5-fluorouracil 300 mg/m2/day for 5 days weekly during RT)
Trial: 14644719
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% once daily (n = 90)
Trial: 14644719
Drug: Combined timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined timolol 0.5% and dorzolamide 2% twice daily (n = 87)
Trial: 29506580
Drug: Starting antiplatelet
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting antiplatelet drugs
Trial: 29506580
Drug: Avoiding antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoiding antiplatelet drugs
Trial: 24678807
Drug: Arotinolol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol combined with nifedipine (30 mg/d nifedipine + 20 mg/d arotinolol)
Trial: 24678807
Drug: Arotinolol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol combined with amlodipine (5 mg/d amlodipine + 20 mg/d arotinolol)
Trial: 24678807
Drug: Arotinolol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arotinolol combined with felodipine (5 mg/d felodipine + 20 mg/d arotinolol)
Trial: 21798784
Drug: Pharmaceutical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical intervention with a pharmacist explaining prescribed drugs and providing a personalized medication timetable
Trial: 21798784
Drug: Pharmaceutical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical intervention with a pharmacist
Trial: 10081699
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone analogue (LH-RHa) started the first day of radiotherapy and administered every 4 weeks over 3 years
Trial: 10081699
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone analogue (LH-RHa) initiated in the last week of radiation therapy and continued until relapse
Trial: 10081699
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy with LH-RHa during and after radiation
Trial: 8608360
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin therapy
Trial: 2200187
Drug: Heparin 5000
RxNorm normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5000 IU + 0.5 mg DHE (HDHE) three times a day
Trial: 2200187
Drug: Acetyl‐salicylic‐acid (ASA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl‐salicylic‐acid (ASA) 0.5 g + dihydroergotamin (DHE) 2.5 mg three times a day
Trial: 7082024
Drug: 5% crude
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% crude coal tar in an absorbent ointment base (Aquaphor)
Trial: 7082024
Drug: Absorbent ointment
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbent ointment base alone
Trial: 12028324
Drug: Frovatriptan 2.5
RxNorm normalized name: frovatriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan 2.5 mg
Trial: 15147247
Drug: Frovatriptan 2.5
RxNorm normalized name: frovatriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan 2.5 mg and Placebo
Trial: 12352234
Drug: Metronidazole 400
RxNorm normalized name: metronidazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 400 mg three times daily for seven days
Trial: 9839847
Drug: C: 25
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C: 25 g creatine monohydrate/day, 5 days
Trial: 9839847
Drug: CC: 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC: 25 g creatine monohydrate/day, 5 days plus 5 g/h during exercise
Trial: 8301790
Drug: 22-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-mg nicotine patch therapy with intensive group counseling for 8 weeks (Study 1)
Trial: 8301790
Drug: 22-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-mg nicotine patch therapy for 4 weeks followed by 11-mg nicotine patch therapy for 2 weeks with brief individual counseling (Study 2)
Trial: 8301790
Drug: 22-mg nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-mg nicotine patch therapy
Trial: 7897117
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Trial: 19921357
Drug: Flurbiprofen 1
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 1 mg kg(‐1) before surgery
Trial: 19921357
Drug: Placebo (lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lipid emulsion 0.1 ml kg(‐1)) before surgery
Trial: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine (CSM) therapy for 2 weeks
Trial: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine (CSM) therapy reinstated for 2 weeks
Trial: 17010568
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy for 2 weeks
Trial: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholestyramine (CSM) therapy after placebo
Trial: 15516022
Drug: Single-dose CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose CF101 (1, 5, or 10 mg)
Trial: 15516022
Drug: Multiple-dose CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose CF101 (2, 3, 4, or 5 mg, 12-hourly for 7 days)
Trial: 15516022
Drug: Single-dose CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose CF101 (5 mg)
Trial: 15516022
Drug: First multiple-dose
RxNorm normalized name: allantoin / benzalkonium chloride Topical Foam [Hands First 4 in 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First multiple-dose CF101 (5 mg)
Trial: 15516022
Drug: After 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 7 days of multiple dosing
Trial: 15516022
Drug: Leucocytosis after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocytosis after CF101 (5 and 10 mg)
Trial: 15689068
Drug: Artesunate (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (3.3 mg/kg on day 1, followed by 1.65 mg/kg for the next four days, total dose = 600 mg)
Trial: 15689068
Drug: Artesunate followed
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate followed by primaquine (15 mg for 14 days)
Trial: 272945
Drug: L‐asparaginase 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐asparaginase 1,000 mu/kg iv q.d. x 10, vincristine 2.0 mg/m2 iv q.w. x 4 and prednisone 40 mg/m2 p.o.q.d. x 28 days
Trial: 27730325
Drug: Conventional dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional dexamethasone nasal spray
Trial: 27730325
Drug: Device using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Device using pressure and vibration to distribute steroid aerosol endonasally
Trial: 25092886
Drug: HRM diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRM diet (300 g/day lean red meat)
Trial: 25092886
Drug: HRM+HAMSB diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRM+HAMSB diet (HRM with 40 g/day butyrylated high amylose maize starch)
Trial: 22561907
Drug: PSA threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA threshold of 4 ng ml(‐1)
Trial: 16780933
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy (OAT)
Trial: 17692112
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic therapy (AT)
Trial: 17692112
Drug: OAT prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAT prescription in 2004
Trial: 26394202
Drug: Vehicle solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution (control group)
Trial: 15351853
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (6.0 x 10(6) KIU) systemically for both groups
Trial: 11110645
Drug: Intranasal (inl)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (inl) immunization with monovalent, live attenuated, cold‐adapted recombinant (CR) or inactivated influenza virus (MIV) vaccine
Trial: 11110645
Drug: Combined inl
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inl (CR or MIV) and im vaccine
Trial: 11110645
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) immunization with MIV
Trial: 9701860
Drug: Medication information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication information procedure
Trial: 8023663
Drug: Midazolam 75
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 75 micrograms.kg-1 followed by continuous infusion of propofol
Trial: 8023663
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg.kg-1 bolus followed by infusion
Trial: 31003677
Drug: 5% grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% grape seed extract ointment
Trial: 31003677
Drug: 2.5% grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% grape seed extract ointment
Trial: 24983681
Drug: Expectant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant treatment
Trial: 19262754
Drug: Rabipur(R) rabies
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabipur(R) rabies vaccine
Trial: 2468896
Drug: Nifedipine, 10
RxNorm normalized name: Nifedipine, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 10 mg p.o.
Trial: 28987445
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of IIV4 and PPV23
Trial: 22677718
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg three times a day, increasing to maximum tolerated dose or 120 mg three times a day for 7 days)
Trial: 17541211
Drug: ACEI temocapril
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI temocapril (T) 2 mg/day
Trial: 17541211
Drug: ARB candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB candesartan (C) 4 mg/day
Trial: 17541211
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (T+C)
Trial: 17541211
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (C+T)
Trial: 17541211
Drug: Nifedipine-CR (N)
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-CR (N) 20 mg/day
Trial: 17541211
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low doses of ACEI and ARB
Trial: 2550046
Drug: Isoprenaline (ISO)
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline (ISO) infusion
Trial: 2550046
Drug: Isoprenaline (ISO)
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline (ISO) bolus injections
Trial: 779587
Drug: Clonidine 0.225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.225 mg daily (mean dosage varied from 0.225 to 0.900 mg)
Trial: 779587
Drug: Practolol 200
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol 200 mg daily (mean dosage varied from 200 to 600 mg)
Trial: 779587
Drug: Chlorothiazide 25
RxNorm normalized name: chlorothiazide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide 25 mg added to clonidine in 15 cases
Trial: 779587
Drug: Chlorothiazide 25
RxNorm normalized name: chlorothiazide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide 25 mg added to practolol in 18 cases
Trial: 25517820
Drug: RMP formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP formulation E
Trial: 25517820
Drug: INH formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH formulations A, B, C, and D
Trial: 25517820
Drug: RMP formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP formulations A, B, C, and D
Trial: 25517820
Drug: INH formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INH formulation E
Trial: 20230611
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review and cognitive behaviour therapy by community pharmacists
Trial: 20230611
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Treatment
Trial: 20230611
Drug: Medication Adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Adherence Report Scale Questionnaire
Trial: 9376578
Drug: Intensive Consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Consolidation Chemotherapy (ICC)